Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III: EFFICACY OF CPX-351 AS FIRST LINE TREATMENT FOR HIGHER RISK (HR) MDS/CMML. A STUDY BY THE GFM. (September 2021)